EAGAN, Minn. -- (BUSINESS WIRE) -- Biothera announced today the acceptance of a poster presentation on the results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer to be held Jan. 6-9 in San Diego.
The company recently completed an open label, multicenter, randomized trial in 90 patients with untreated advanced NSCLC. The study evaluated Biothera’s immunotherapeutic drug candidate, Imprime PGG®, with cetuximab (Erbitux®), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapy combination alone.
Biothera previously announced that the study had met its primary endpoint with a statistically significant improvement in objective response rate in the treatment group. Researchers noted that a subset of subjects who tested positive for a biomarker linked to the ability of their immune cells to bind and respond to Imprime PGG showed further improvement in response rates and a six-month improvement in overall survival.
Richard Huhn, M.D., Biothera senior vice president and medical director, will present the data in a session entitled, “Imprime PGG improves the efficacy of carboplatin, paclitaxel and cetuximab chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC).”
Date: Poster Session A on Tuesday, Jan. 7 from 12:30 p.m. - 2:30 p.m.
Location: Woodstock room, fourth floor
Poster Board Number: A26
About Imprime PGG®
Imprime PGG is a novel immunomodulatory drug in development as a cancer therapy. Innate immune cells are the most abundant immune cells in the body and are normally responsible for pathogen killing, but not anti-tumor activity. However, Imprime PGG has been shown to bind to neutrophils and monocytes and redirect their killing ability to reduce tumor growth and enhance long-term survival. This targeted mechanism is synergistic with multiple anti-tumor monoclonal antibodies, providing the potential to improve patient outcomes in a wide range of cancer indications. Imprime PGG has demonstrated marked improvements in overall response rates in multiple clinical trials for colorectal cancer, KRAS-mutant colorectal cancer and chronic lymphocytic leukemia. Imprime PGG is currently in a Phase 3 clinical trial for advanced colorectal cancer and a Phase 2 NSCLC study with bevacizumab (Avastin®).
For more information, visit our website at www.biothera.com/pharma.
About Biothera, the Immune Health Company
Biothera is a U.S. biotechnology company dedicated to improving immune health. The company is developing pharmaceuticals that engage the innate immune system to fight cancer.